Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Show me how to use this page

Poseida Therapeutics Inc. Stock

Price
Target price
€2.61

€2.61

15.140%
0.344
15.140%
€4.00
 
02.05.24 / Tradegate WKN: A2PEYK / Name: Poseida Therapeutics Inc. / Stock / ? /
Please give a prediction to see the opinions of the community
Buy
None
Sell
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Pros and Cons of Poseida Therapeutics Inc. in the next few years
Wizard

Poseida Therapeutics Inc. Stock

Poseida Therapeutics Inc. dominated the market today, gaining €0.34 (15.140%).
With 0 Sell predictions and 1 Buy predictions the community sentiment towards the Poseida Therapeutics Inc. stock is not clear.
As a result the target price of 4 € shows a very positive potential of 53.49% compared to the current price of 2.61 € for Poseida Therapeutics Inc..
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Poseida Therapeutics Inc. stock. Negative votes have not been in the majority for any criteria for this stock
What does Poseida Therapeutics Inc. do?

Pros and Cons of Poseida Therapeutics Inc. in the next few years

Pros
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
?
S********** s********
Cons
?
G***** c******* t* c**********
?
B****
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Your Opinion
Legal notice

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2023-11-25

Delving into the financial health of Poseida Therapeutics Inc., one’s initial impression might be grounded in the complex narrative that its numbers reveal. With biotech companies, particularly those in the developmental stage like Poseida, the financials often paint a picture not of current profitability but of potential future value based on research and development opportunities. Poseida Therapeutics, with its conspicuous absence of positive earnings and a substantial market capitalization of approximately $224.457 million, provides a telling example of a high-risk, high-reward opportunity that is synonymous with the biotech sector.

General Impression of Financials

A broad analysis reveals that Poseida Therapeutics is operating with a significant level of financial risk. The negative EBITDA of -$131.285 million indicates that the company is not currently generating positive earnings before interest, taxes, depreciation, and amortization. Coupled with an operating margin in the negative, specifically -387.32%, and a negative profit margin at -264.07%, the figures depict a company that is burning through cash. The Total Revenue (TTM) standing at $49.759 million, with a downward trajectory in quarterly revenue growth year-over-year of -92%, could warrant investor concerns regarding revenue streams.

Show more
Register To Post